Spending review could mean cuts in Wales
Some public services are likely to face cuts if the NHS swallows extra funding announced for Wales in Chancellor Rachel Reeves's spending review, experts have said.There is a warning that "tough choices loom", even though the budget is expected to grow over the next three years.Labour said it was investing in public services by boosting the Welsh government's budget.But Plaid Cymru accused Wales' First Minister Eluned Morgan of "asking for very little and getting exactly that".
The Welsh government can raise taxes, but most of what it spends comes in a grant from the Treasury.Its funding will be £22.4bn a year on average over the next three years as a result of the spending review.
The Institute for Fiscal Studies (IFS), an independent think tank, said funding for the day-to-day running of public services would grow about 1.2% above inflation."While an increase overall, that will likely require tough choices and indeed real terms cuts for some services," the IFS's David Phillips said."Increases in funding for the Welsh NHS could easily absorb most, if not all, of this increase."He said Welsh Finance Secretary Mark Drakeford will "have to decide carefully which areas to prioritise and which to cut back".About half the Welsh government's budget is already spent on healthcare.Waiting times for hospital treatment have risen to record highs in recent years.On Wednesday, the chancellor announced a real-terms increase of 3% to day-to-day funding for the NHS in England.That will result in extra funding for Welsh ministers to spend as they wish.However, Guto Ifan from the Wales Governance Centre warned: "If the Welsh government decided to transfer that money to the health service in Wales, which would still be below the historical growth in health spending, it would mean difficult settlements for everything else in the budget."I would imagine that the Welsh government would have to make cuts to services outside health under this settlement."
Reeves' spending review reveals how much funding will be available after next May's Senedd election.She also announced £445m for new rail projects in Wales, following years of complaints that Wales has not had a fair share of spending.She backed plans for five new stations in Cardiff, Newport and Monmouthshire, and rail upgrades in north Wales.First Minister Eluned Morgan said: "Wales will see significant extra investment in rail infrastructure, coal tips safety and Welsh communities will see real benefits that improve lives and create opportunities."Treasury minister Torsten Bell said there would be "record levels of spending happening in the Welsh government" and said previous Conservative governments "consistently let down Wales" on capital spending which pays for infrastructure.Opponents said the cash fell short of what Wales needed and criticised a ten-year timeline for the scheme - Labour sources said most of the cash would be spent much sooner.Plaid Cymru finance spokesperson, Heledd Fychan, said: "Public services, already teetering on the brink in Wales under Labour face further cuts as a consequence of Labour's First Minister asking for very little and getting exactly that."Welsh Conservative Senedd leader Darren Millar said the amount of rail funding was "shameful"."Today's rail spending announcement is an insult to the people of Wales," he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Western Telegraph
37 minutes ago
- Western Telegraph
Parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Jasper enjoys a range of hobbies (Family handout/PA) Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'
Western Telegraph
37 minutes ago
- Western Telegraph
‘Trojan horse' treatment given green light for NHS use
The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest. It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment. Paul Silvester received his treatment at the Royal Hallamshire Hospital in Sheffield (handout/PA) It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use. NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can now be offered to patients whose cancer has progressed or not responded to another first-line treatment. The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' 🚨 Do you know the key symptoms of #myeloma? 🚨 Help us spread the word by sharing this post! Early diagnosis makes all the difference. If something feels off, don't wait – talk to your GP!#BloodCancerAwarenessMonth @MyelomaUK — DKMS UK | We Delete Blood Cancer (@DKMS_uk) September 6, 2024 Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly-used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future. 'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. 'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
Daily Mail
38 minutes ago
- Daily Mail
What's the first thing you'd do if you won the EuroMillions? Our poll reveals number one priority…
EuroMillions fever is in full swing, with the record £208million jackpot still up for grabs in tonight's triple rollover. Those who are in it to win it are likely to daydream and do the mental spend of such an unfeasibly large sum… even if the odds are completely stacked against them. But if you did defy the extreme odds and win a life-changing sum of cash, what is the very first thing you'd do? That's a question we put to This is Money and Mail Online readers, with 23,405 votes cast, asking: If you won the lottery what would you do first? The options were pay off mortgage, buy a house, save/invest, travel and help family/friends. While it is likely all five of those categories will be on the agenda for the winner of a plus-£200million lottery win, the poll revealed that helping family and friends was the priority, with 35 per cent of people giving that answer. Pay off mortgage and buy a house both received 21 per cent of the vote, travel received 15 per cent and save/invest was bottom of the pile at 9 per cent. But while family and friends are top priority, gifting large sums of money should be considered carefully, warns Matt Swatton of wealth management firm Cannacord Wealth. He is a wealth planning director who has advised lottery winners on the unexpected challenges winners face and how they can navigate them in the past. He said: 'Many winners want to share their good fortune with family and friends. 'While gifting can be incredibly rewarding, it also comes with emotional and financial implications. 'A large gift can change the recipient's life - and your relationship with them. 'You also need to consider affordability - make sure you can afford the gift without compromising your own future.' Winners who are gifting money to friends and family will also need to think about the tax implications of gifting. In the UK, gifts are generally free from inheritance tax if you live for seven years after making them 'If someone is gifting and they survive for seven years - happy days,' says financial planner Graham Dixon of wealth management firm Evelyn Partners where he also advises lottery winners on how to manage their fortunes. 'But for gifts that don't fall within the donor's nil rate band - should the donor die, the individual could be liable for tax if the lottery winner dies and the gift made was over £325,000,' he adds. To get around this, the winner could set aside money to make a provision for any tax bill the recipient may face if the donor dies within seven years. They could also set up a trust or take out an insurance policy that directly matches the tax liability as it reduces over seven years. It is insured on the life of the lottery winner and recipients can used this to pay for any inheritance tax bill if the donor dies. Dixon adds: 'When it comes to gifting, many winners naturally wish to make provision for younger members of their family, typically children or grandchildren. 'It's important to consider the order that gifts are made, especially if earmarking money for your children's future using a trust in order to avoid unnecessary tax charges.' On top of the £208million jackpot, the EuroMillions draw this Friday will also have 13 guaranteed £1million prizes in the UK as part of the raffle element, with this Friday being the 'unlucky' 13th.
